• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002566.SZ
Share

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Stocks

CN¥ 6.95Last Updated 12.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CN¥ 350.14M

CN¥ 6.95
Key Takeaways

Risk factor

High price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Jilin Jian Yisheng Pharmaceutical Co., Ltd. is an enterprise based in Ji'an, China, established in 1997. The company specializes in the production and distribution of a diverse array of goods across the Chinese market. Its offerings include various pharmaceutical products, traditional Chinese herbal medicines, cosmetic items, and food products. Within its medical and health divisions, the firm provides goods in formats such as capsules, injections, tablets, and granules, with a particular emphasis on specialized medicinal products derived from Ginseng, as well as a selection of bee-related products.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive' on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 15:36

Morning in New York: Oil Caught Between De-escalation and the Risk of New Attacks

12.10.2026 15:03

The Nobel Prize in Economics was awarded to the authors of new approaches to crisis management

12.10.2026 14:48

Slow but sure—a tsunami: IMF chief warns that AI is hitting the labor market and government budgets

12.10.2026 14:28

The CEOs of Broadcom and Intel have identified the main challenge facing AI development. It is not a chip shortage.

12.10.2026 13:09

The Saudis announced that they had intercepted new missiles. Riyadh promises stable oil supplies

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026